NCT07099651

Brief Summary

Spinocerebellar ataxias are a group of rare neurodegenerative diseases, clinically and genetically highly heterogeneous, with an estimated mean prevalence of 2.7 per 100,000 population. The term "spinocerebellar ataxia" or "SCA" is often used for ataxias of genetic origin of autosomal dominant transmission, which are the subject of this study. Recent studies of social cognition in patients with genetic cerebellar pathologies, and autosomal dominant spinocerebellar ataxia in particular, are still few and far between (around 15 studies), and seem to highlight impairment of basic emotion recognition and theory of mind skills. That said, data have very often been collected on very small samples of patients (sometimes in case study format). They also remain contradictory, including in the examination of the cerebellar anatomoclinical correlates of the deficits. Thus, the question arises as to whether patients with spinocerebellar ataxia also show impairments in emotion recognition and cognitive and affective theory of mind in more ecologically valid dynamic and interactive assessment situations.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
32mo left

Started Dec 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Dec 2025Jan 2029

First Submitted

Initial submission to the registry

July 17, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

August 1, 2025

Completed
4 months until next milestone

Study Start

First participant enrolled

December 9, 2025

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2028

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2029

Last Updated

February 5, 2026

Status Verified

February 1, 2026

Enrollment Period

2.9 years

First QC Date

July 17, 2025

Last Update Submit

February 2, 2026

Conditions

Outcome Measures

Primary Outcomes (7)

  • to assess the social cognition with the Facial Emotion Recognition Test from classical approach

    Facial Emotion Recognition Test evaluates the ability to recognize 6 fundamental and universal emotions: happiness, anger, sadness, fear, disgust and contempt. Each emotion is expressed by a different face at 9 levels of expressive intensity, ranging from 20% to 100%

    Baseline

  • to assess the social cognition with the Faux Pas Test from classical approach

    Faux Pas Test: in its shortened 10-story version, it assesses the ability to recognize social awkwardness (or faux-pas). Fictitious stories are presented to the person, in paper format: 5 stories contain faux-pas and 5 others do not. The person can reread them as many times as necessary, and must detect whether "someone said something they shouldn't have, or something awkward". If this is the case, she is asked 5 additional questions to assess her understanding of the clumsiness. Each story is followed by 2 comprehension questions, to rule out a comprehension problem. This task takes 20 minutes to administer. The test produces different scores: the higher the score, the better the performance.

    Baseline

  • to assess the social cognition with the Reading the Mind in the Eyes test from classical approach

    Reading the Mind in the Eyes test: Thirty-six photographs of gazes (male and female) are presented to the participant, who is asked to select from 4 expression proposals the one that seems most appropriate to the subject's affective mental state (what he or she may be feeling). A lexicon that can be consulted at will is provided to the subject to compensate for any uncertainties concerning the proposed items. The maximum score is 36 (1 point per correctly chosen item). The test takes 15 to 20 minutes to complete.

    Baseline

  • to assess the social cognition with the sequencing test from classical approach

    sequencing test: sequential arrangement of 12 scenarios, all consisting of 4 images in the format of short comic strips. They represent mechanical (non-social) events and social scripts including true (4 scenarios) and false beliefs (4 scenarios). Subjects are asked to put each image sequence, presented in random order, back into chronological order. There are 4 non-social scenarios, 4 true-belief scenarios and 4 false-belief scenarios for a 12-point score. The test begins with 2 practice trials. The test lasts 20 minutes.

    Baseline

  • to assess the social cognition with the French Emotion Evaluation Test from ecological approach

    French Emotion Evaluation Test: audiovisual, ecological and valid emotion recognition test. It tests subjects' ability to recognize basic emotions expressed by other people. It comprises 35 short video sequences (15 to 30 seconds) plus an example item. In each of these sequences, actors interpret everyday situations associated with one of the 6 basic emotions: joy, sadness, anger, surprise, disgust and fear. The test produces a total response score of between 0 and 35.

    Baseline

  • to assess the social cognition with the Movie for the Assessment of Social Cognition Test from ecological approach

    evaluates theory of mind in dynamic modality. It was adapted and validated in French (MASC-VF) as part of a partnership between Patricia Garel's team (Hopital Universitaire de Sainte-Justine, Montreal, Quebec) and Isabelle Amado's team (Centre Hospitalier Sainte-Anne, Service Hospitalo-Universitaire, Paris, France). This test assesses both the affective and cognitive sides of theory of mind, and also includes six control questions to rule out a comprehension problem. The test takes around 40 minutes to administer. The test will assess the cognitive and affective theory-of-mind abilities of ALS patients in comparison with those of matched control subjects. The MASC calculates 5 scores: 1 comprehension score, 1 correct response score ranging from 0 to 45 points and 3 error scores (wrong answers are divided into 3 categories: under-interpretation error, over-interpretation error and no interpretation). The higher the score of correct answers, the better the performance.

    Baseline

  • to assess the social cognition with the social problem-solving test from interactionist approach

    This test has been developped at Angers . A total of 10 stories involving social problems will be proposed. For 5 of them, the participant will have to produce verbal solutions, and for the other 5, act them out in a social role-playing situation, with a partner. The test lasts 40 minutes.

    Baseline

Secondary Outcomes (30)

  • Search for and describe any deficits in social cognition by identifying pathological treshold with Facial Emotion Recognition Test

    Baseline

  • Research and describe any deficits in social cognition by identifying pathological treshold with false step test

    Baseline

  • Research and describe any deficits in social cognition by identifying pathological treshold with Reading the Mind in the Eyes test

    Baseline

  • Search for and describe any deficits in social cognition by identifying pathological treshold with sequencing test

    Baseline

  • Research and describe any deficits in social cognition by identifying pathological treshold with French Emotion Evaluation Test

    Baseline

  • +25 more secondary outcomes

Study Arms (2)

patients autosomal dominant spinocerebellar ataxia

ACTIVE COMPARATOR
Other: tests

healthy patients

ACTIVE COMPARATOR
Other: tests

Interventions

testsOTHER

neuropsychological tests + Neuroimaging

healthy patientspatients autosomal dominant spinocerebellar ataxia

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • For all participants:
  • Men or women aged 18 and over
  • At least 7 years' schooling (CEP level)
  • Ability to read, write and speak French
  • Signed informed consent to participate in the study
  • For patients :
  • \- With molecularly confirmed autosomal dominant spinocerebellar ataxia (SCA1, 2, 3, 6, 7, 27B)
  • For controls:
  • \- With no neurological pathology (questioning and neurological examination)

You may not qualify if:

  • For patients and controls:
  • Simultaneous participation in another protocol that may interfere with the measurement of the criteria of interest
  • Physical or cultural factors likely to interfere with test performance
  • History likely to interfere with cognition (stroke, cranioencephalic trauma, other neurodegenerative disease, epilepsy, learning disability, alcohol dependence syndrome, psychiatric disorders...)
  • Persons with contraindications to MRI scans
  • Pregnant, nursing or parturient women
  • Persons deprived of their liberty by judicial or administrative decision
  • Persons under compulsory psychiatric care
  • Persons subject to a legal protection measure
  • Persons unable to express their consent
  • Persons not affiliated to or not benefiting from a social security scheme (beneficiary or beneficiary entitled)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Angers

Angers, 49933, France

RECRUITING

MeSH Terms

Conditions

Spinocerebellar Ataxias

Condition Hierarchy (Ancestors)

Cerebellar AtaxiaCerebellar DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesSpinocerebellar DegenerationsSpinal Cord DiseasesHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesAtaxiaDyskinesiasNeurologic ManifestationsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Philippe Allain, professor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 17, 2025

First Posted

August 1, 2025

Study Start

December 9, 2025

Primary Completion (Estimated)

November 1, 2028

Study Completion (Estimated)

January 1, 2029

Last Updated

February 5, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.

Shared Documents
STUDY PROTOCOL
Time Frame
The data will be shared after signing a negotiated data transfer agreement ( data access agreement), for the duration specified in the agreement.
Access Criteria
The data will be made available via secure transfer (sharing platform approved by the university hospital: BlueFiles or Oodrive).

Locations